Small-vessel vasculitic syndromes such as Wegener granulomatosis and microscopic polyangiitis, which are associated with circulating antineutrophil cytoplasmic autoantibodies, are an important cause of renal failure. Current immunosuppressive regimens based on cyclophosphamide have significantly improved survival in patients with these conditions. However, such treatments are toxic, increase the risk of infection and do not cure the disease; fresh approaches are, therefore, required. An increased understanding of the pathogenesis of these syndromes has allowed the rational use of newer therapies such as rituximab, an anti-CD20 chimeric monoclonal antibody that depletes B cells. Further understanding of the disease pathogenesis is crucial to the development of novel targeted therapies, which are urgently required to improve patient prognosis. Future potential therapies include molecules that block signaling pathways that are essential in the pathogenesis of these diseases.
Current treatment regimens for antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides that are based on cyclophosphamide have improved survival but are associated with significant morbidity
ANCAs are pathogenic antibodies that activate neutrophils and cause inflammation
B cells have a key role in the pathogenesis of ANCA-associated vasculitides and their removal using B-cell-depleting therapeutic antibodies offers hope for the future and is being investigated in randomized trials
Signaling pathways in neutrophils activated by ANCAs differ from those induced by immune complexes; molecules that block these pathways have shown benefit in animal models, providing hope for less-toxic therapies
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Savage, C. O. S., Harper, L. & Adu, D. Primary systemic vasculitis. Lancet 349, 553–558 (1997).
Watts, R. A., Lane, S. E., Bentham, G. & Scott, D. G. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 43, 414–419 (2000).
Mukhtyar, C. et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann. Rheum. Dis. 67, 1004–1010 (2008).
Watts, R. et al. Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann. Rheum. Dis. 60, 170–172 (2001).
Mukhtyar, C. et al. EULAR Recommendations for the management of primary small and medium vessel vasculitis. Ann. Rheum. Dis. doi:10.1136/ard.2008.088096 (2008).
de Groot, K., Adu, D. & Savage, C. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol. Dial. Transplant. 16, 2018–2027 (2001).
Jayne, D. R. et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 18, 2180–2188 (2007).
de Groot, K. et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52, 2461–2469 (2005).
Jayne, D. et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 349, 36–44 (2003).
Metzler, C., Fink, C., Lamprecht, P., Gross, W. L. & Reinhold-Keller, E. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 43, 315–320 (2004).
Langford, C. A., Talar-Williams, C. & Sneller, M. C. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum. 51, 278–283 (2004).
Flossmann, O. & Jayne, D. R. Maintaining remission in a patient with vasculitis. Nat. Clin. Pract. Rheumatol. 4, 499–504 (2008).
Booth, A. D. et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am. J. Kidney Dis. 41, 776–784 (2003).
Azathioprine; cyclophosphamide; prednisolone in Therapeutic Drugs (ed. Dollery, C.) p. A181–A184; C366–C372; P199–P220 (London, Churchill Livingstone, 1991).
de Leeuw, K. et al. Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann. Rheum. Dis. 64, 753–759 (2005).
Hogan, S. L. et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann. Intern. Med. 143, 621–631 (2005).
Pagnoux, C. et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 58, 2908–2918 (2008).
Hoffman, G. S. et al. Wegener's granulomatosis: an analysis of 158 patients. Ann. Intern. Med. 116, 488–498 (1992).
Guillevin, L. et al. A prospective, multi-center randomized trial comparing steroids and pulse cyclophosphomide versus steroids and oral cyclophosphomide in the treatment of generalised Wegener's granulomatosis. Arthritis Rheum. 40, 2187–2198 (1997).
Stegeman, C. A., Cohen Tervaert, J. W., Manson, W. L. & Kallenberg, C. G. M. Persistent nasal carriage of Staphylococcus aureus and relapse rate of Wegener's granulomatosis. Presented at the 4th International Workshop on ANCA, May 28–30, Lübeck, Germany (1992).
Hagen, E. et al. Diagnostic value of standardized assays for antineutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int. 53, 743–753 (1998).
Boomsma, M. M. et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 43, 2025–2033 (2000).
Bansal, P. J. & Tobin, M. C. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase–antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann. Allergy Asthma Immunol. 93, 398–401 (2004).
Xiao, H. et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 110, 955–963 (2002).
Xiao, H. et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am. J. Pathol. 167, 39–45 (2005).
Schreiber, A., Xiao, H., Falk, R. J. & Jennette, J. C. Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies. J. Am. Soc. Nephrol. 17, 3355–3364 (2006).
Little, M. A. et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte–microvascular interactions in vivo. Blood 106, 2050–2058 (2005).
Harper, L., Cockwell, P., Adu, D. & Savage, C. Neutrophil priming and apoptosis in ANCA-associated vasculitis. Kidney Int. 59, 1729–1738 (2001).
Muller Kubold, A., Mesander, G., Stegeman, C., Kallenberg, C. & Cohen Tervaert, J. Are circulating neutrophils intravascularly activated in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides? Clin. Exp. Immunol. 114, 491–499 (1998).
Huugen, D. et al. Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-α. Am. J. Pathol. 167, 47–58 (2005).
Falk, R. J., Terrell, R. S., Charles, L. A. & Jennette, J. C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc. Natl Acad. Sci. USA 87, 4115–4119 (1990).
Condliffe, A. M., Chilvers, E. R., Haslett, C. & Dransfield, I. Priming differentially regulates neutrophil adhesion molecule expression/function. Immunology 89, 105–111 (1996).
Williams, J. M. et al. Activation of the Gi heterotrimeric G protein by ANCA IgG F(ab')2 fragments is necessary but not sufficient to stimulate the recruitment of those downstream mediators used by intact ANCA IgG. J. Am. Soc. Nephrol. 14, 661–669 (2003).
Hewins, P., Williams, J. M., Wakelam, M. J. & Savage, C. O. Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcγ receptors and CD18. J. Am. Soc. Nephrol. 15, 796–808 (2004).
Radford, D., Lord, J. & Savage, C. The activation of the neutrophil respiratory burst by anti-neutrophil cytoplasm autoantibody (ANCA) from patients with systemic vasculitis requires tyrosine kinases and protein kinase C activation. Clin. Exp. Immunol. 118, 171–179 (1999).
Ben-Smith, A., Dove, S., Martin, A., Wakelam, M. & Savage, C. Anti-neutrophil cytoplasmic autoantibodies from patients with systemic vasculitis activate neutrophils via distinct signalling cascades compared to conventional Fcγ receptor ligation. Blood 981, 1448–1455 (2001).
Williams, J. M. & Savage, C. O. Characterization of the regulation and functional consequences of p21ras activation in neutrophils by antineutrophil cytoplasm antibodies. J. Am. Soc. Nephrol. 16, 90–96 (2005).
Reumaux, D., Kuijpers, T. W., Hordijk, P. L., Duthilleul, P. & Roos, D. Involvement of Fcγ receptors and β2 integrins in neutrophil activation by anti-proteinase-3 or anti-myeloperoxidase antibodies. Clin. Exp. Immunol. 134, 344–350 (2003).
Savage, C. O., Harper, L. & Holland, M. New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis. Curr. Opin. Rheumatol. 14, 15–22 (2002).
Nolan, S. L. et al. Mechanisms of ANCA-mediated leukocyte-endothelial cell interactions in vivo. J. Am. Soc. Nephrol. 19, 973–984 (2008).
Lamprecht, P. Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Clin. Exp. Immunol. 141, 201–210 (2005).
Giscombe, R., Wang, X. B., Kakoulidou, M. & Lefvert, A. K. Characterization of the expanded T-cell populations in patients with Wegener's granulomatosis. J. Intern. Med. 260, 224–230 (2006).
Marinaki, S. et al. Abnormalities of CD4 T cell subpopulations in ANCA-associated vasculitis. Clin. Exp. Immunol. 140, 181–191 (2005).
Abdulahad, W. H. et al. Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum. 56, 2080–2091 (2007).
Thewissen, M. et al. CD4+CD28null T cells in autoimmune disease: pathogenic features and decreased susceptibility to immunoregulation. J. Immunol. 179, 6514–6523 (2007).
Voswinkel, J. et al. B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann. Rheum. Dis. 65, 859–864 (2006).
Hooke, D., Gee, D. & Atkins, R. Leukocyte analysis using monoclonal antibodies in glomerulonephritis. Kidney Int. 31, 964–972 (1987).
Popa, E. R., Stegeman, C. A., Bos, N. A., Kallenberg, C. G. & Tervaert, J. W. Differential B- and T-cell activation in Wegener's granulomatosis. J. Allergy Clin. Immunol. 103, 885–894 (1999).
Culton, D. A. et al. Similar CD19 dysregulation in two autoantibody-associated autoimmune diseases suggests a shared mechanism of B-cell tolerance loss. J. Clin. Immunol. 27, 53–68 (2007).
Voswinkel, J., Muller, A. & Lamprecht, P. Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production. Ann. NY Acad. Sci. 1051, 12–19 (2005).
Stassen, P. M., Cohen Tervaert, J. W. & Stegeman, C. A. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann. Rheum. Dis. 66, 798–802 (2007).
Joy, M. S., Hogan, S. L., Jennette, J. C., Falk, R. J. & Nachman, P. H. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol. Dial. Transplant. 20, 2725–2732 (2005).
Hu, W. et al. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol. Dial. Transplant. 23, 1307–1312 (2008).
European Vasculitis Study Group Active Clinical Trials http://www.vasculitis.org/acttrials.htm
Diegel, M. L., Nadler, S. G. & Kiener, P. A. In vivo administration of 15-deoxyspergulin inhibits antigen-presenting cell stimulation of T cells and NF-κB activation. Int. Immunopharmacol. 2, 1451–1464 (2002).
Tepper, M. A., Nadler, S. G., Esselstyn, J. M. & Sterbenz, K. G. Deoxyspergualin inhibits κ light chain expression in 70Z/3 pre-B cells by blocking lipopolysaccharide-induced NF-κB activation. J. Immunol. 155, 2427–2436 (1995).
Kalsch, A. I. et al. In vivo effects of cyclic administration of 15-deoxyspergualin on leucocyte function in patients with Wegener's granulomatosis. Clin. Exp. Immunol. 146, 455–462 (2006).
Flossmann, O. et al. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann. Rheum. Dis. doi:10.1136/ard.2008.092429 (2008).
Schmitt, W. H. et al. Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol. Dial. Transplant. 20, 1083–1092 (2005).
Walsh, M. & Jayne, D. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney Int. 72, 676–682 (2007).
Ramos-Casals, M., Brito-Zeron, P., Munoz, S. & Soto, M. J. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 87, 345–364 (2008).
Yokoyama, H. et al. Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature. Int. J. Hematol. 88, 443–447 (2008).
Smith, K. G., Jones, R. B., Burns, S. M. & Jayne, D. R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 54, 2970–2982 (2006).
Ferraro, A. J., Drayson, M. T., Savage, C. O. & MacLennan, I. C. Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with rituximab. Eur. J. Immunol. 38, 292–298 (2008).
Hoyer, B. F. et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J. Exp. Med. 199, 1577–1584 (2004).
Cassese, G. et al. Inflamed kidneys of NZB/W mice are a major site for the homeostasis of plasma cells. Eur. J. Immunol. 31, 2726–2732 (2001).
Taylor, R. P. & Lindorfer, M. A. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr. Opin. Immunol. 20, 444–449 (2008).
Assi, L. K. et al. Tumor necrosis factor α activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. Arthritis Rheum. 56, 1776–1786 (2007).
Krumbholz, M. et al. BAFF is elevated in serum of patients with Wegener's granulomatosis. J. Autoimmun. 25, 298–302 (2005).
Ding, C. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opin. Biol. Ther. 8, 1805–1814 (2008).
Schmitt, W. H. et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 65, 1440–1448 (2004).
Walsh, M., Chaudhry, A. & Jayne, D. R. Long-term follow-up of relapsing/refractory ANCA associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann. Rheum. Dis. 67, 1322–1327 (2008).
Sansom, D. M. & Walker, L. S. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol. Rev. 212, 131–148 (2006).
Linsley, P. S. et al. Human B7–1 (CD80) and B7–2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1, 793–801 (1994).
Greene, J. L. et al. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J. Biol. Chem. 271, 26762–26771 (1996).
Zhou, Y. et al. An analysis of CTLA-4 and proinflammatory cytokine genes in Wegener's granulomatosis. Arthritis Rheum. 50, 2645–2650 (2004).
Kremer, J. M. et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 144, 865–876 (2006).
Kremer, J. M. et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 58, 953–963 (2008).
Reynolds, J. et al. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J. Clin. Invest. 105, 643–651 (2000).
Little, M. A. et al. Therapeutic effect of anti-TNF–α antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 17, 160–169 (2006).
Khan, S. B. et al. Antibody blockade of TNF-α reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int. 67, 1812–1820 (2005).
Booth, A. et al. Prospective study of TNFα blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 15, 717–721 (2004).
Stone, J. H. et al. Etanercept combined with conventional treatment in Wegener's granulomatosis. Arthritis Rheum. 44, 1149–1154 (2001).
Group, W. R. Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 352, 351–361 (2005).
Wung, P. K. et al. Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis. Arthritis Rheum. 59, 746–753 (2008).
Stone, J. H. et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. 54, 1608–1618 (2006).
Wung, P. et al. Risk factors for herpes zoster in immunocompromised patients: experience from the Wegener's granulomatosis etanercept trial. Kidney Blood Press. Res. 28, 175 (2005).
Osterman, M. T. & Lichtenstein, G. R. Current and future anti-TNF therapy for inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 10, 195–207 (2007).
Nishimoto, N. et al. Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann. Rheum. Dis. doi:10.1136/ard.2008.092866 (2008).
Pine, P. R. et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin. Immunol. 124, 244–257 (2007).
Weinblatt, M. E. et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58, 3309–3318 (2008).
Smith, J. et al. Syk inhibitor is effective in treatment of experimental glomerulonephritis [abstract]. J. Am. Soc. Nephrol. 19, 63A (2008).
Kälsch, A. I. et al. Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis? Clin. Exp. Immunol. 151, 391–398 (2008).
Paniagua, R. T. et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J. Clin. Invest. 116, 2633–2642 (2006).
Hirsch, E. et al. Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation. Science 287, 1049–1053 (2000).
Li, Z. et al. Roles of PLC-β2 and -β3 and PI3Kγ in chemoattractant-mediated signal transduction. Science 287, 1046–1049 (2000).
Camps, M. et al. Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11, 936–943 (2005).
Barber, D. F. et al. PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 11, 933–935 (2005).
Clarke, H. C. et al. Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis. J. Am. Soc. Nephrol. 14, 848–854 (2003).
Braun, T. & Fenaux, P. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia. Br. J. Haematol. 141, 576–586 (2008).
Gratwohl, A. et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant. 35, 869–879 (2005).
Daikeler, T. et al. Haematopoietic stem cell transplantation for vasculitis including Behçet's disease and polychondritis: a retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a review of the literature. Ann. Rheum. Dis. 66, 202–207 (2007).
Statkute, L. et al. Autologous non-myeloablative haematopoietic stem cell transplantation for refractory systemic vasculitis. Ann. Rheum. Dis. 67, 991–997 (2008).
Kotter, I., Daikeler, T., Amberger, C., Tyndall, A. & Kanz, L. Autologous stem cell transplantation of treatment-resistant systemic vasculitis—a single center experience and review of the literature. Clin. Nephrol. 64, 485–489 (2005).
The authors declare no competing financial interests.
About this article
Cite this article
Pallan, L., Savage, C. & Harper, L. ANCA-associated vasculitis: from bench research to novel treatments. Nat Rev Nephrol 5, 278–286 (2009). https://doi.org/10.1038/nrneph.2009.45
Takayasu arteritis: A distinct syndrome of large vessel vasculitis: A view point by late Professor Paul Bacon
International Journal of Rheumatic Diseases (2019)
Nihon Shoni Jinzobyo Gakkai Zasshi (2012)
Orbital pseudotumor: A single precursor clinical manifestation of Wegener granulomatosis in a ten year old boy
Open Journal of Pediatrics (2012)
Nephrology Dialysis Transplantation (2011)